MRZ 99030

Drug Profile

MRZ 99030

Alternative Names: MRZ-99030

Latest Information Update: 26 Apr 2016

Price : $50

At a glance

  • Originator Merz Pharmaceuticals GmbH
  • Class Antiglaucomas; Neuroprotectants; Small molecules
  • Mechanism of Action Protein aggregation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Glaucoma

Most Recent Events

  • 01 Dec 2013 Merz Pharmaceuticals completes a phase I trial for Glaucoma in Germany (NCT01714960)
  • 29 Nov 2013 Merz Pharmaceuticals completes enrolment in its phase I trial for Glaucoma in Germany (NCT01714960)
  • 26 Jul 2013 Phase-I development is ongoing in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top